BERWYN, Pa.--(BUSINESS WIRE)--Amzell B.V. (Amzell), a specialist development pharmaceutical company, and Amring Pharmaceuticals Inc. (Amring), a niche generics and value-driven brand company, announced today that they will be in attendance at the 2021 American Epilepsy Society (AES) Annual Meeting. The meeting will be held from Dec 3 to Dec 7, 2021, at McCormick Place West in Chicago, IL.
BERWYN, Pa.--(BUSINESS WIRE)--Amzell,nB.V., a specialty pharmaceutical development company based in The nNetherlands, and Amring Pharmaceuticals Inc. (Amring), a niche brand andngeneric pharmaceutical company based in Berwyn, PA, announced today nthat their lead product in the collaboration, AMZ002, has entered Phase nIII Clinical Trial in the U.S. for treatment of infantile epileptic ndisease. AMZ002, a purified synthetic polypeptide, offers an alternativento existing FDA-approved treatment for epileptic seizures. This productnreceived both Rare Pediatric Disease and Orphan-Drug Designations.
BERWYN, Pa.--(BUSINESS WIRE)--Amzell, B.V., a specialty pharmaceutical development company based in The Netherlands, and Amring Pharmaceuticals Inc. (Amring), a niche brand and generic pharmaceutical company based in Berwyn, PA, announced today that their lead product in the collaboration, AMZ002, has entered Phase III Clinical Trial in the U.S. for treatment of infantile epileptic disease. AMZ002, a purified synthetic polypeptide, offers an alternative to existing FDA-approved treatment for epileptic seizures. This product received both Rare Pediatric Disease and Orphan-Drug Designations.
Specialist development pharmaceutical company Amzell B.V has concluded discussions with the FDA ahead of initiating a phase 3 trial of its new treatment for infantile epileptic disease, AMZ002.